Azora Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Azora Therapeutics (AZR) granted one new non-executive employee an option to buy 40,000 common shares as a hiring inducement. The grant took effect on November 16, 2026, under the 2026 Employment Inducement Equity Incentive Plan. The option has a $3.81-per-share exercise price, equal to the stock’s closing price on that date, and a ten-year term.
The option vests over four years: 25% on the first anniversary of the grant date and the rest in equal monthly installments, subject to continued service through each vesting date.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Option for 40,000 common shares could dilute existing shareholders if exercised at $3.81 per share.
Key Figures
- Option award
- 40,000 shares
- Granted to one new non-executive employee
- Exercise price
- $3.81 per share
- Closing stock price on the grant's effective date
- Option term
- 10 years
- Term of the option award
- Vesting period
- Four years
- 25% vests on the first anniversary; the remainder vests in equal monthly installments
Key Terms
exercise price financial
vesting financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
LOS ANGELES, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Azora Therapeutics, Inc. (NASDAQ: AZR) (the “Company”), a biopharmaceutical company developing treatments for serious inflammatory diseases, announced today that the Compensation Committee of its Board of Directors granted an option to purchase 40,000 shares of the Company’s common stock under the Azora Therapeutics, Inc. 2026 Employment Inducement Equity Incentive Plan (the “2026 Inducement Plan”) to one new non-executive employee as an inducement material to such person entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The option award has an exercise price of
The 2026 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of the Company or its parent or subsidiaries, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4).
About Azora Therapeutics, Inc.
Azora Therapeutics is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. The company was launched out of Stanford University after being incubated in the translational medicine SPARK program. Azora owns worldwide royalty-free rights to its technology, which is based on the development of oral agonists of the aryl hydrocarbon receptor. Azora’s lead program is AT177, a proprietary colon-targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, in development for ulcerative colitis. More information on Azora can be found on the company’s website at www.AzoraTherapeutics.com.
Investor Contact:
Mike Moyer
Managing Director
LifeSci Advisors, LLC
Phone: (617) 328-4326
Email: mmoyer@lifesciadvisors.com
Media Contact:
Ashley Biladeau
Inizio Evoke Comms
Email: Ashley.Biladeau@inizioevoke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.